These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 9332546)

  • 1. Relapsing infection due to Enterobacter species: lessons of heterogeneity.
    Medeiros AA
    Clin Infect Dis; 1997 Aug; 25(2):341-2. PubMed ID: 9332546
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.
    Sanders WE; Tenney JH; Kessler RE
    Clin Infect Dis; 1996 Sep; 23(3):454-61. PubMed ID: 8879764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bloodstream infections caused by Enterobacter species: predictors of 30-day mortality rate and impact of broad-spectrum cephalosporin resistance on outcome.
    Kang CI; Kim SH; Park WB; Lee KD; Kim HB; Oh MD; Kim EC; Choe KW
    Clin Infect Dis; 2004 Sep; 39(6):812-8. PubMed ID: 15472813
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cefepime Therapy for Monomicrobial Enterobacter cloacae Bacteremia: Unfavorable Outcomes in Patients Infected by Cefepime-Susceptible Dose-Dependent Isolates.
    Lee NY; Lee CC; Li CW; Li MC; Chen PL; Chang CM; Ko WC
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7558-63. PubMed ID: 26416853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid emergence of resistance to cefepime during treatment.
    Limaye AP; Gautom RK; Black D; Fritsche TR
    Clin Infect Dis; 1997 Aug; 25(2):339-40. PubMed ID: 9332545
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment outcomes in patients with third-generation cephalosporin-resistant Enterobacter bacteremia.
    O'Neal CS; O'Neal HR; Daniels TL; Talbot TR
    Scand J Infect Dis; 2012 Oct; 44(10):726-32. PubMed ID: 22681412
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid emergence of resistance to cefepime during treatment.
    Acar J
    Clin Infect Dis; 1998 Jun; 26(6):1484-6. PubMed ID: 9636899
    [No Abstract]   [Full Text] [Related]  

  • 8. The origin, by mutation, of high level resistance to ceftazidime and cefotaxime in a clinical isolate of Enterobacter cloacae.
    Blahová J; Lesická-Hupková M; Králiková K; Krcméry V; Mikovicová A
    J Chemother; 1996 Aug; 8(4):266-9. PubMed ID: 8873831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cefepime and amikacin synergy in vitro and in vivo against a ceftazidime-resistant strain of Enterobacter cloacae.
    Mimoz O; Jacolot A; Padoin C; Tod M; Samii K; Petitjean O
    J Antimicrob Chemother; 1998 Mar; 41(3):367-72. PubMed ID: 9578163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beta-lactam-resistant Enterobacter bacteremia in febrile neutropenic patients receiving monotherapy.
    Johnson MP; Ramphal R
    J Infect Dis; 1990 Oct; 162(4):981-3. PubMed ID: 2205658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a new cefepime-clavulanate ESBL Etest to detect extended-spectrum beta-lactamases in an Enterobacteriaceae strain collection.
    Stürenburg E; Sobottka I; Noor D; Laufs R; Mack D
    J Antimicrob Chemother; 2004 Jul; 54(1):134-8. PubMed ID: 15150168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Broad-spectrum beta-lactam resistance in Enterobacter: emergence during treatment and mechanisms of resistance.
    Olson B; Weinstein RA; Nathan C; Kabins SA
    J Antimicrob Chemother; 1983 Apr; 11(4):299-310. PubMed ID: 6602122
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the in vitro and in vivo antibacterial activities of cefepime (BMY-28142) with ceftazidime, cefuzonam, cefotaxime and cefmenoxime.
    Masuyoshi S; Hiraoka M; Inoue M; Tomatsu K; Hirano M; Mitsuhashi S
    Drugs Exp Clin Res; 1989; 15(1):1-10. PubMed ID: 2663406
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple beta-lactam resistance in Enterobacter cloacae following ceftazidime monotherapy.
    Black AS; Cohen J
    Lancet; 1985 Aug; 2(8450):331-2. PubMed ID: 2862496
    [No Abstract]   [Full Text] [Related]  

  • 16. Emergence of resistance to ceftazidime during therapy for Enterobacter cloacae infections.
    Quinn JP; DiVincenzo CA; Foster J
    J Infect Dis; 1987 May; 155(5):942-7. PubMed ID: 3549922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of cefepime therapy for Enterobacter bacteraemia, with special emphasis on febrile neutropenic patients.
    Lee JA; Kang CI; Joung MK; Moon SY; Chung DR; Ko KS; Peck KR; Song JH
    Scand J Infect Dis; 2010 Jul; 42(6-7):557-9. PubMed ID: 20214544
    [No Abstract]   [Full Text] [Related]  

  • 18. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia.
    Siedner MJ; Galar A; Guzmán-Suarez BB; Kubiak DW; Baghdady N; Ferraro MJ; Hooper DC; O'Brien TF; Marty FM
    Clin Infect Dis; 2014 Jun; 58(11):1554-63. PubMed ID: 24647022
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
    Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
    Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Occurrence of cefotaxime-resistant Enterobacter during therapy of cardiac surgery patients.
    Weinstein RA
    Chemioterapia; 1985 Feb; 4(1):110-2. PubMed ID: 3986939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.